http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 09 Jul 2026 16:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Vor+Biopharma+Inc.++++++++For%3A+Jul+07++Filed+by%3A+ZACCARDELLI+DAVID/26753131.html si-local-file:///var/storage/secattach/20260709/26753131.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Vor+Biopharma+Inc.++++++++For%3A+Jul+07++Filed+by%3A+ZACCARDELLI+DAVID/26753131.html Thu, 09 Jul 2026 16:01:00 -0400 O.48279457 VOR http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Vor+Biopharma+Inc.++++++++For%3A+Jul+07++Filed+by%3A+ZACCARDELLI+DAVID/26753131.html si-local-file:///var/storage/secattach/20260709/26753131.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Vor+Biopharma+Inc.++++++++For%3A+Jul+07++Filed+by%3A+ZACCARDELLI+DAVID/26753131.html Thu, 09 Jul 2026 16:01:00 -0400 O.48279457 VOR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vor+Biopharma+Inc.++++++++For%3A+Jul+07++Filed+by%3A+ZACCARDELLI+DAVID/26753132.html si-local-file:///var/storage/secattach/20260709/26753132.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vor+Biopharma+Inc.++++++++For%3A+Jul+07++Filed+by%3A+ZACCARDELLI+DAVID/26753132.html Thu, 09 Jul 2026 16:01:00 -0400 O.48279457 VOR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vor+Biopharma+Inc.++++++++For%3A+Jul+07++Filed+by%3A+ZACCARDELLI+DAVID/26753132.html si-local-file:///var/storage/secattach/20260709/26753132.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vor+Biopharma+Inc.++++++++For%3A+Jul+07++Filed+by%3A+ZACCARDELLI+DAVID/26753132.html Thu, 09 Jul 2026 16:01:00 -0400 O.48279457 VOR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vor+Biopharma+Inc.++++++++For%3A+Jul+06/26741744.html si-local-file:///var/storage/secattach/20260707/26741744.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vor+Biopharma+Inc.++++++++For%3A+Jul+06/26741744.html Tue, 07 Jul 2026 16:04:00 -0400 O.48279457 VOR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vor+Biopharma+Inc.++++++++For%3A+Jul+06/26741744.html si-local-file:///var/storage/secattach/20260707/26741744.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vor+Biopharma+Inc.++++++++For%3A+Jul+06/26741744.html Tue, 07 Jul 2026 16:04:00 -0400 O.48279457 VOR http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html <p>Vor Bio (Nasdaq: VOR) has appointed David Zaccardelli, Pharm.D., to its board of directors, the clinical-stage biotechnology company announced, based on a press release statement.</p> <p>Zaccardelli previously served as President and Chief Executive Officer of Verona Pharma from February 2020 until the company was acquired by Merck for $10 billion in October 2025. During that period, Verona completed two Phase 3 trials, received FDA approval, and launched Ohtuvayre for chronic obstructive pulmonary disease. The company raised more than $1 billion under his leadership.</p> <p>Prior to Verona, Zaccardelli served as President and CEO of Dova Pharmaceuticals, which was acquired by Swedish Orphan Biovitrum http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html Tue, 07 Jul 2026 16:01:17 -0400 A.02472879 A.08629400 A.10141387 A.36987393 A.50114033 A.50200233 O.00394185 O.01656413 O.20059298 O.22806100 O.31404518 O.34165625 O.48279457 VOR http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html <p>Vor Bio (Nasdaq: VOR) has appointed David Zaccardelli, Pharm.D., to its board of directors, the clinical-stage biotechnology company announced, based on a press release statement.</p> <p>Zaccardelli previously served as President and Chief Executive Officer of Verona Pharma from February 2020 until the company was acquired by Merck for $10 billion in October 2025. During that period, Verona completed two Phase 3 trials, received FDA approval, and launched Ohtuvayre for chronic obstructive pulmonary disease. The company raised more than $1 billion under his leadership.</p> <p>Prior to Verona, Zaccardelli served as President and CEO of Dova Pharmaceuticals, which was acquired by Swedish Orphan Biovitrum http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html Tue, 07 Jul 2026 16:01:17 -0400 A.02472879 A.08629400 A.10141387 A.36987393 A.50114033 A.50200233 O.00394185 O.01656413 O.20059298 O.22806100 O.31404518 O.34165625 O.48279457 VOR http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html <p>Vor Bio (Nasdaq: VOR) has appointed David Zaccardelli, Pharm.D., to its board of directors, the clinical-stage biotechnology company announced, based on a press release statement.</p> <p>Zaccardelli previously served as President and Chief Executive Officer of Verona Pharma from February 2020 until the company was acquired by Merck for $10 billion in October 2025. During that period, Verona completed two Phase 3 trials, received FDA approval, and launched Ohtuvayre for chronic obstructive pulmonary disease. The company raised more than $1 billion under his leadership.</p> <p>Prior to Verona, Zaccardelli served as President and CEO of Dova Pharmaceuticals, which was acquired by Swedish Orphan Biovitrum http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html Tue, 07 Jul 2026 16:01:17 -0400 A.02472879 A.08629400 A.10141387 A.36987393 A.50114033 A.50200233 O.00394185 O.01656413 O.20059298 O.22806100 O.31404518 O.34165625 O.48279457 VOR http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html <p>Vor Bio (Nasdaq: VOR) has appointed David Zaccardelli, Pharm.D., to its board of directors, the clinical-stage biotechnology company announced, based on a press release statement.</p> <p>Zaccardelli previously served as President and Chief Executive Officer of Verona Pharma from February 2020 until the company was acquired by Merck for $10 billion in October 2025. During that period, Verona completed two Phase 3 trials, received FDA approval, and launched Ohtuvayre for chronic obstructive pulmonary disease. The company raised more than $1 billion under his leadership.</p> <p>Prior to Verona, Zaccardelli served as President and CEO of Dova Pharmaceuticals, which was acquired by Swedish Orphan Biovitrum http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html Tue, 07 Jul 2026 16:01:17 -0400 A.02472879 A.08629400 A.10141387 A.36987393 A.50114033 A.50200233 O.00394185 O.01656413 O.20059298 O.22806100 O.31404518 O.34165625 O.48279457 VOR http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html <p>Vor Bio (Nasdaq: VOR) has appointed David Zaccardelli, Pharm.D., to its board of directors, the clinical-stage biotechnology company announced, based on a press release statement.</p> <p>Zaccardelli previously served as President and Chief Executive Officer of Verona Pharma from February 2020 until the company was acquired by Merck for $10 billion in October 2025. During that period, Verona completed two Phase 3 trials, received FDA approval, and launched Ohtuvayre for chronic obstructive pulmonary disease. The company raised more than $1 billion under his leadership.</p> <p>Prior to Verona, Zaccardelli served as President and CEO of Dova Pharmaceuticals, which was acquired by Swedish Orphan Biovitrum http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html Tue, 07 Jul 2026 16:01:17 -0400 A.02472879 A.08629400 A.10141387 A.36987393 A.50114033 A.50200233 O.00394185 O.01656413 O.20059298 O.22806100 O.31404518 O.34165625 O.48279457 VOR http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html <p>Vor Bio (Nasdaq: VOR) has appointed David Zaccardelli, Pharm.D., to its board of directors, the clinical-stage biotechnology company announced, based on a press release statement.</p> <p>Zaccardelli previously served as President and Chief Executive Officer of Verona Pharma from February 2020 until the company was acquired by Merck for $10 billion in October 2025. During that period, Verona completed two Phase 3 trials, received FDA approval, and launched Ohtuvayre for chronic obstructive pulmonary disease. The company raised more than $1 billion under his leadership.</p> <p>Prior to Verona, Zaccardelli served as President and CEO of Dova Pharmaceuticals, which was acquired by Swedish Orphan Biovitrum http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html Tue, 07 Jul 2026 16:01:17 -0400 A.02472879 A.08629400 A.10141387 A.36987393 A.50114033 A.50200233 O.00394185 O.01656413 O.20059298 O.22806100 O.31404518 O.34165625 O.48279457 VOR http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html <p>Vor Bio (Nasdaq: VOR) has appointed David Zaccardelli, Pharm.D., to its board of directors, the clinical-stage biotechnology company announced, based on a press release statement.</p> <p>Zaccardelli previously served as President and Chief Executive Officer of Verona Pharma from February 2020 until the company was acquired by Merck for $10 billion in October 2025. During that period, Verona completed two Phase 3 trials, received FDA approval, and launched Ohtuvayre for chronic obstructive pulmonary disease. The company raised more than $1 billion under his leadership.</p> <p>Prior to Verona, Zaccardelli served as President and CEO of Dova Pharmaceuticals, which was acquired by Swedish Orphan Biovitrum http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html Tue, 07 Jul 2026 16:01:17 -0400 A.02472879 A.08629400 A.10141387 A.36987393 A.50114033 A.50200233 O.00394185 O.01656413 O.20059298 O.22806100 O.31404518 O.34165625 O.48279457 VOR http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html <p>Vor Bio (Nasdaq: VOR) has appointed David Zaccardelli, Pharm.D., to its board of directors, the clinical-stage biotechnology company announced, based on a press release statement.</p> <p>Zaccardelli previously served as President and Chief Executive Officer of Verona Pharma from February 2020 until the company was acquired by Merck for $10 billion in October 2025. During that period, Verona completed two Phase 3 trials, received FDA approval, and launched Ohtuvayre for chronic obstructive pulmonary disease. The company raised more than $1 billion under his leadership.</p> <p>Prior to Verona, Zaccardelli served as President and CEO of Dova Pharmaceuticals, which was acquired by Swedish Orphan Biovitrum http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html Tue, 07 Jul 2026 16:01:17 -0400 A.02472879 A.08629400 A.10141387 A.36987393 A.50114033 A.50200233 O.00394185 O.01656413 O.20059298 O.22806100 O.31404518 O.34165625 O.48279457 VOR http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html <p>Vor Bio (Nasdaq: VOR) has appointed David Zaccardelli, Pharm.D., to its board of directors, the clinical-stage biotechnology company announced, based on a press release statement.</p> <p>Zaccardelli previously served as President and Chief Executive Officer of Verona Pharma from February 2020 until the company was acquired by Merck for $10 billion in October 2025. During that period, Verona completed two Phase 3 trials, received FDA approval, and launched Ohtuvayre for chronic obstructive pulmonary disease. The company raised more than $1 billion under his leadership.</p> <p>Prior to Verona, Zaccardelli served as President and CEO of Dova Pharmaceuticals, which was acquired by Swedish Orphan Biovitrum http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html Tue, 07 Jul 2026 16:01:17 -0400 A.02472879 A.08629400 A.10141387 A.36987393 A.50114033 A.50200233 O.00394185 O.01656413 O.20059298 O.22806100 O.31404518 O.34165625 O.48279457 VOR http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html <p>Vor Bio (Nasdaq: VOR) has appointed David Zaccardelli, Pharm.D., to its board of directors, the clinical-stage biotechnology company announced, based on a press release statement.</p> <p>Zaccardelli previously served as President and Chief Executive Officer of Verona Pharma from February 2020 until the company was acquired by Merck for $10 billion in October 2025. During that period, Verona completed two Phase 3 trials, received FDA approval, and launched Ohtuvayre for chronic obstructive pulmonary disease. The company raised more than $1 billion under his leadership.</p> <p>Prior to Verona, Zaccardelli served as President and CEO of Dova Pharmaceuticals, which was acquired by Swedish Orphan Biovitrum http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html Tue, 07 Jul 2026 16:01:17 -0400 A.02472879 A.08629400 A.10141387 A.36987393 A.50114033 A.50200233 O.00394185 O.01656413 O.20059298 O.22806100 O.31404518 O.34165625 O.48279457 VOR http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html <p>Vor Bio (Nasdaq: VOR) has appointed David Zaccardelli, Pharm.D., to its board of directors, the clinical-stage biotechnology company announced, based on a press release statement.</p> <p>Zaccardelli previously served as President and Chief Executive Officer of Verona Pharma from February 2020 until the company was acquired by Merck for $10 billion in October 2025. During that period, Verona completed two Phase 3 trials, received FDA approval, and launched Ohtuvayre for chronic obstructive pulmonary disease. The company raised more than $1 billion under his leadership.</p> <p>Prior to Verona, Zaccardelli served as President and CEO of Dova Pharmaceuticals, which was acquired by Swedish Orphan Biovitrum http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html Tue, 07 Jul 2026 16:01:17 -0400 A.02472879 A.08629400 A.10141387 A.36987393 A.50114033 A.50200233 O.00394185 O.01656413 O.20059298 O.22806100 O.31404518 O.34165625 O.48279457 VOR http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html <p>Vor Bio (Nasdaq: VOR) has appointed David Zaccardelli, Pharm.D., to its board of directors, the clinical-stage biotechnology company announced, based on a press release statement.</p> <p>Zaccardelli previously served as President and Chief Executive Officer of Verona Pharma from February 2020 until the company was acquired by Merck for $10 billion in October 2025. During that period, Verona completed two Phase 3 trials, received FDA approval, and launched Ohtuvayre for chronic obstructive pulmonary disease. The company raised more than $1 billion under his leadership.</p> <p>Prior to Verona, Zaccardelli served as President and CEO of Dova Pharmaceuticals, which was acquired by Swedish Orphan Biovitrum http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html Tue, 07 Jul 2026 16:01:17 -0400 A.02472879 A.08629400 A.10141387 A.36987393 A.50114033 A.50200233 O.00394185 O.01656413 O.20059298 O.22806100 O.31404518 O.34165625 O.48279457 VOR http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html <p>Vor Bio (Nasdaq: VOR) has appointed David Zaccardelli, Pharm.D., to its board of directors, the clinical-stage biotechnology company announced, based on a press release statement.</p> <p>Zaccardelli previously served as President and Chief Executive Officer of Verona Pharma from February 2020 until the company was acquired by Merck for $10 billion in October 2025. During that period, Verona completed two Phase 3 trials, received FDA approval, and launched Ohtuvayre for chronic obstructive pulmonary disease. The company raised more than $1 billion under his leadership.</p> <p>Prior to Verona, Zaccardelli served as President and CEO of Dova Pharmaceuticals, which was acquired by Swedish Orphan Biovitrum http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html Tue, 07 Jul 2026 16:01:17 -0400 A.02472879 A.08629400 A.10141387 A.36987393 A.50114033 A.50200233 O.00394185 O.01656413 O.20059298 O.22806100 O.31404518 O.34165625 O.48279457 VOR http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html <p>Vor Bio (Nasdaq: VOR) has appointed David Zaccardelli, Pharm.D., to its board of directors, the clinical-stage biotechnology company announced, based on a press release statement.</p> <p>Zaccardelli previously served as President and Chief Executive Officer of Verona Pharma from February 2020 until the company was acquired by Merck for $10 billion in October 2025. During that period, Verona completed two Phase 3 trials, received FDA approval, and launched Ohtuvayre for chronic obstructive pulmonary disease. The company raised more than $1 billion under his leadership.</p> <p>Prior to Verona, Zaccardelli served as President and CEO of Dova Pharmaceuticals, which was acquired by Swedish Orphan Biovitrum http://www.streetinsider.com/Board+Changes/Vor+Bio+names+David+Zaccardelli+to+its+board+of+directors/26741683.html Tue, 07 Jul 2026 16:01:17 -0400 A.02472879 A.08629400 A.10141387 A.36987393 A.50114033 A.50200233 O.00394185 O.01656413 O.20059298 O.22806100 O.31404518 O.34165625 O.48279457 VOR http://www.streetinsider.com/Press+Releases/Vor+Bio+Appoints+David+Zaccardelli+to+Board+of+Directors/26741681.html <p align="justify">BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D., to its Board of Directors. With more than 20 years of biopharmaceutical leadership experience, Dr. Zaccardelli has successfully built and led companies through late-stage development, regulatory approval, and commercial launch.</p> <p align="justify">“We are excited to welcome David to the Board of Directors at an important stage in the company’s evolution,” said Jean-Paul Kress, M.D., Chairman and Chief Executive Officer of Vor Bio. “David is a proven biotech http://www.streetinsider.com/Press+Releases/Vor+Bio+Appoints+David+Zaccardelli+to+Board+of+Directors/26741681.html Tue, 07 Jul 2026 16:01:00 -0400 A.02472879 A.08629400 A.10141387 A.36987393 A.50114033 A.50200233 O.00394185 O.01656413 O.20059298 O.22806100 O.31404518 O.34165625 O.48279457 VOR http://www.streetinsider.com/Press+Releases/Vor+Bio+Appoints+David+Zaccardelli+to+Board+of+Directors/26741681.html <p align="justify">BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D., to its Board of Directors. With more than 20 years of biopharmaceutical leadership experience, Dr. Zaccardelli has successfully built and led companies through late-stage development, regulatory approval, and commercial launch.</p> <p align="justify">“We are excited to welcome David to the Board of Directors at an important stage in the company’s evolution,” said Jean-Paul Kress, M.D., Chairman and Chief Executive Officer of Vor Bio. “David is a proven biotech http://www.streetinsider.com/Press+Releases/Vor+Bio+Appoints+David+Zaccardelli+to+Board+of+Directors/26741681.html Tue, 07 Jul 2026 16:01:00 -0400 A.02472879 A.08629400 A.10141387 A.36987393 A.50114033 A.50200233 O.00394185 O.01656413 O.20059298 O.22806100 O.31404518 O.34165625 O.48279457 VOR http://www.streetinsider.com/Press+Releases/Vor+Bio+Appoints+David+Zaccardelli+to+Board+of+Directors/26741681.html <p align="justify">BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D., to its Board of Directors. With more than 20 years of biopharmaceutical leadership experience, Dr. Zaccardelli has successfully built and led companies through late-stage development, regulatory approval, and commercial launch.</p> <p align="justify">“We are excited to welcome David to the Board of Directors at an important stage in the company’s evolution,” said Jean-Paul Kress, M.D., Chairman and Chief Executive Officer of Vor Bio. “David is a proven biotech http://www.streetinsider.com/Press+Releases/Vor+Bio+Appoints+David+Zaccardelli+to+Board+of+Directors/26741681.html Tue, 07 Jul 2026 16:01:00 -0400 A.02472879 A.08629400 A.10141387 A.36987393 A.50114033 A.50200233 O.00394185 O.01656413 O.20059298 O.22806100 O.31404518 O.34165625 O.48279457 VOR http://www.streetinsider.com/Press+Releases/Vor+Bio+Appoints+David+Zaccardelli+to+Board+of+Directors/26741681.html <p align="justify">BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D., to its Board of Directors. With more than 20 years of biopharmaceutical leadership experience, Dr. Zaccardelli has successfully built and led companies through late-stage development, regulatory approval, and commercial launch.</p> <p align="justify">“We are excited to welcome David to the Board of Directors at an important stage in the company’s evolution,” said Jean-Paul Kress, M.D., Chairman and Chief Executive Officer of Vor Bio. “David is a proven biotech http://www.streetinsider.com/Press+Releases/Vor+Bio+Appoints+David+Zaccardelli+to+Board+of+Directors/26741681.html Tue, 07 Jul 2026 16:01:00 -0400 A.02472879 A.08629400 A.10141387 A.36987393 A.50114033 A.50200233 O.00394185 O.01656413 O.20059298 O.22806100 O.31404518 O.34165625 O.48279457 VOR http://www.streetinsider.com/Press+Releases/Vor+Bio+Appoints+David+Zaccardelli+to+Board+of+Directors/26741681.html <p align="justify">BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D., to its Board of Directors. With more than 20 years of biopharmaceutical leadership experience, Dr. Zaccardelli has successfully built and led companies through late-stage development, regulatory approval, and commercial launch.</p> <p align="justify">“We are excited to welcome David to the Board of Directors at an important stage in the company’s evolution,” said Jean-Paul Kress, M.D., Chairman and Chief Executive Officer of Vor Bio. “David is a proven biotech http://www.streetinsider.com/Press+Releases/Vor+Bio+Appoints+David+Zaccardelli+to+Board+of+Directors/26741681.html Tue, 07 Jul 2026 16:01:00 -0400 A.02472879 A.08629400 A.10141387 A.36987393 A.50114033 A.50200233 O.00394185 O.01656413 O.20059298 O.22806100 O.31404518 O.34165625 O.48279457 VOR